Director Charles J. Casamento filed a Form 144 notice of proposed sale of 80,555 shares of Eton Pharmaceuticals, Inc. common stock, submitted on November 10, 2026, through broker Raymond James and Associates Inc.
Key Highlights
- Seller and role: Charles J. Casamento is identified in the filing as a Director of Eton Pharmaceuticals, Inc.
- Shares proposed for sale: 80,555 shares of common stock, with an aggregate market value of $5,341,735.71 according to the filing.
- Shares outstanding: The filing reports 28,583,135 shares of common stock outstanding.
- Approximate date of sale: November 10, 2026, executed through Raymond James and Associates Inc., 880 Carillon Parkway, St. Petersburg, FL 33716.
- Acquisition history: The shares were acquired via four separate grants from the issuer, dated February 20, 2019 (12,500 shares), March 12, 2020 (27,400 shares), May 3, 2020 (19,655 shares), and February 7, 2022 (29,000 shares).
- Prior three-month sales: The filing reports nothing to report for securities sold during the past three months.
- Exchange listed: The securities are listed on NASDAQ.
Casamento's Proposed Sale of Granted Shares in Eton Pharmaceuticals
According to the Form 144 filing, Charles J. Casamento, a Director of Eton Pharmaceuticals, Inc. (NASDAQ:ETON), has provided notice of a proposed sale of 80,555 shares of the company's common stock. The filing lists an aggregate market value of $5,341,735.71 for the proposed sale, against a total of 28,583,135 shares outstanding as reported in the document. The broker identified for the transaction is Raymond James and Associates Inc., located at 880 Carillon Parkway, St. Petersburg, FL 33716.
The filing discloses that the shares proposed for sale were acquired through four separate grant transactions from the issuer. These grants occurred on February 20, 2019 (12,500 shares), March 12, 2020 (27,400 shares), May 3, 2020 (19,655 shares), and February 7, 2022 (29,000 shares). No cash purchase price is associated with any of these acquisitions, as all were received as grants from Eton Pharmaceuticals, Inc.
The filing states that Casamento reported no sales of securities in the three months prior to the notice date of November 10, 2026. The notice was signed by Rashida Mitchell, described as "duly authorized representative of Raymond James and Associates, Inc., as attorney-in-fact for Charles J Casamento." The filer's representation in the form states that the seller does not know of any material adverse information regarding the current and prospective operations of the issuer that has not been publicly disclosed.
What Was Disclosed
Eton Pharmaceuticals Director Charles J. Casamento filed a Form 144 on November 10, 2026, proposing the sale of 80,555 shares of common stock, all acquired via grants from the issuer between 2019 and 2022, with an aggregate market value of $5,341,735.71.



Please wait processing your request...